NKTX Stock Analysis: Buy, Sell, or Hold?
NKTX - Nkarta, Inc. Common Stock
$3.03
0.24 (8.60%)
▲
5d:
+10.58%
30d:
+0.0%
90d:
+38.99%
BUY
HIGH Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 11, 2026
Get Alerted When NKTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: NKTX shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
✅ BUY SIGNAL: NKTX shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
In-depth Analysis How we analyze
Valuation Analysis: NKTX is currently trading at $3.03, which is considered slightly high relative to its 30-day fair value range of $2.58 to $3.07.
Technical Outlook: Technically, NKTX is in a strong uptrend. Immediate support is located at $2.32, while resistance sits at $3.34. The stock is showing strong short-term momentum, up 8.6% recently.
Market Sentiment: NKTX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (19th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $11.20 (+269.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, NKTX is in a strong uptrend. Immediate support is located at $2.32, while resistance sits at $3.34. The stock is showing strong short-term momentum, up 8.6% recently.
Market Sentiment: NKTX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (19th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $11.20 (+269.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$2.58 -
$3.07
Company Quality Score
58/100
(HOLD)
Options IV Signal
19th percentile
(COMPLACENCY WARNING)
Volume Confirmation
HIGH
Confidence Score
87.5%
All Signals
- BULLISH: Options cheap (IV 19th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+8.6%)
- BULLISH: Trading 269.6% below Wall St target ($11.20)
Trading Range Analysis
30-Day Trading Range
$2.58 -
$3.07
Current vs Trading Range
SLIGHTLY HIGH
Expected Move (7 Days)
±$0.33
(10.8%)
Support & Resistance Levels
Support Level
$2.32
Resistance Level
$3.34
Current Trend
Strong Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.76
Wall Street Target
$11.20
(+269.6%)
Share & Embed Analysis
Last updated: June 24, 2026 9:45 AM ET
Data refreshes hourly during market hours. Next update: 10:45 AM
Data refreshes hourly during market hours. Next update: 10:45 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NKTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Nadir Mahmood
SELL
5649 shares
2026-01-15
Paul J Hastings
SELL
26046 shares
2026-01-15
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 56 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 57 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 61 BUY |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 54 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 59 HOLD |
